Eli Lilly and Company (LLY) Stake Decreased by Charter Trust Co.

Charter Trust Co. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,160 shares of the company’s stock after selling 2,398 shares during the quarter. Charter Trust Co.’s holdings in Eli Lilly and were worth $7,749,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. grew its position in shares of Eli Lilly and by 0.5% during the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock worth $313,000 after buying an additional 17 shares in the last quarter. Northwest Quadrant Wealth Management LLC grew its position in shares of Eli Lilly and by 0.5% during the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after buying an additional 19 shares in the last quarter. Pillar Pacific Capital Management LLC grew its position in shares of Eli Lilly and by 0.3% during the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock worth $595,000 after buying an additional 20 shares in the last quarter. Guardian Life Insurance Co. of America grew its position in shares of Eli Lilly and by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 3,747 shares of the company’s stock worth $315,000 after buying an additional 25 shares in the last quarter. Finally, Joel Isaacson & Co. LLC grew its position in shares of Eli Lilly and by 1.5% during the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after buying an additional 50 shares in the last quarter. 75.77% of the stock is owned by institutional investors and hedge funds.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the transaction, the insider now owns 124,265,804 shares of the company’s stock, valued at $10,491,761,831.72. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders sold 825,000 shares of company stock worth $68,456,650. Insiders own 0.20% of the company’s stock.

Several brokerages recently issued reports on LLY. Piper Jaffray Companies restated a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a research note on Thursday, August 31st. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a research note on Monday, July 17th. Jefferies Group LLC restated a “buy” rating and set a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Berenberg Bank restated a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research note on Thursday, July 27th. Finally, BidaskClub upgraded Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $88.27.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Equities Focus and is owned by of Equities Focus. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.equitiesfocus.com/2017/09/17/eli-lilly-and-company-lly-stake-decreased-by-charter-trust-co.html.

Shares of Eli Lilly and Company (NYSE LLY) traded down 0.76% on Friday, hitting $82.44. The stock had a trading volume of 5,374,504 shares. The company has a market cap of $86.97 billion, a price-to-earnings ratio of 35.67 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The firm has a 50 day moving average price of $80.89 and a 200-day moving average price of $82.06.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.86 earnings per share. Analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date was Friday, August 11th. Eli Lilly and’s dividend payout ratio is currently 90.04%.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply